Market Newsdesk

SCOTTSDALE, Ariz., Aug. 27, 2026 (GLOBE NEWSWIRE) — Caliber (Nasdaq: CWD), a real estate-focused alternative asset manager, today announced the formation of Caliber Tokenization Services, LLC (“CTS”), a new division that provides full-service real-world asset (RWA) tokenization engagements to family offices that own and operate significant real estate portfolios, under the brand, Tokenized by Caliber.

CTS was created following the successful launch of Caliber’s first tokenized real-estate investment, PURE Pickleball & Padel, earlier this month. The Company assembled the proprietary smart contracts, expert implementation team, and execution experience that tokenization requires, and recognized Caliber could apply this to both to its own portfolio and the portfolios of family offices. This implementation solves for ownership records spread across dozens of entities & family members, providing enhanced visibility into what they own and what it is worth. Once the family’s ownership is digital, transfers, gifts, and estate planning are simplified and additional options for access to liquidity, that do not require the sale of a building, may emerge.

“For 17 years we have worked alongside families that own large portfolios of real estate, and we watched the same problems repeat,” said Chris Loeffler, CEO of Caliber. “When we began tokenizing our own funds, we realized the technology solves those problems. Many of these families are Caliber clients, and through discussions it became clear that the family would prefer to hire a real estate firm that has already tokenized its investments, rather than assemble a dozen technology contracts on its own. Tokenization does not make a building operate better, but it does make owning the building better for every member of the family. Real estate is the largest asset class in the world and among the least tokenized. We are building the on-ramp for the private portfolios that need it most.”

The launch places Caliber inside one of the fastest-moving trends in institutional finance. Tokenized real-world assets have grown to more than $38 billion, excluding stablecoins, according to RWA.xyz as of August 2026, while real estate, valued at $393 trillion by Savills and the world’s largest store of wealth, represents less than one percent of that tokenized value. Caliber believes it is among the first U.S. public companies to tokenize its own private real estate fund and to offer tokenization of private real estate portfolios as a service. CTS launches with a deliberate focus on family offices, and the platform is designed to expand into additional service lines as the market develops.

CTS delivers tokenization as a single, white-glove engagement. The division contracts in bulk with institutional providers across the tokenization ecosystem and combines those services with Caliber’s proprietary smart contracts and implementation process. Clients receive one partner, one contract, and a guided implementation typically completed in six to eight weeks. Institutional providers in the tokenization industry gain access to a relatively untouched asset class and an implementation partner in Caliber that speaks both languages.

CTS serves two client groups: Caliber’s own funds and offerings, and family offices that own at least $50 million of real estate. Engagements are designed around the outcomes families care about, including a single, secure, current picture of each family member’s ownership; automated portfolio valuation updates; simplified transfers between approved family members; practical execution of gifting and estate planning strategies; and optionality for liquidity through borrowing or resale of equity, which remains entirely under the family’s control.

Because each engagement is custom, and because the Company is tokenizing its own portfolio in parallel, CTS has capacity for a limited number of family office engagements through the end of 2026, with expanded capacity expected in 2027. Family offices and their advisors can learn more and begin a confidential conversation at TokenizedByCaliber.com.

Caliber is establishing CTS as a new stream of fee-based service revenue for the platform. During 2026, while CTS completes the implementation phase across Caliber’s own portfolio, it will operate with limited third-party capacity. The Company expects the division to provide incremental revenue contributions, and, as such, the Company is not revising its projections upward at this time. Caliber reaffirms its current 2026 revenue projections and believes CTS strengthens the Company’s ability to achieve them. As the business develops, the Company expects CTS to provide an increasingly meaningful revenue contribution and expects to report CTS as its own revenue line item for Caliber’s platform in the future.

About Caliber (CaliberCos Inc.)
Caliber (Nasdaq: CWD) is a real estate-focused alternative asset manager with over $2.6 billion in Managed Assets and a 17-year track record investing in middle-market hospitality and multifamily real estate. The Company pairs an institutional-quality asset management platform with a boutique, hands-on investment approach focused on value creation in underserved market segments. Investors can participate in Caliber through its publicly traded equity (Nasdaq: CWD), and through its private real estate investment funds for accredited investors and financial professionals. For more information, visit caliberco.com.

Forward-Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 26, 2026, and other reports filed with the SEC thereafter. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law. Nothing in this press release is an offer to sell, or a solicitation of an offer to buy, any security. Caliber Tokenization Services provides technology and administrative services, and tokenization does not guarantee any outcome, including liquidity.

CONTACTS:

Caliber Investor Relations:

Ilya Grozovsky
+1 480-214-1915
[email protected]

Media Relations:

Philip Robertson
+1 917-498-4711
[email protected]

Data supports ongoing registration Phase 3 trial in r/r PTCL, Phase 2 trial in atopic dermatitis and planned trials for hidradenitis suppurativa and asthma 

Data in T cell lymphoma demonstrated anti-tumor activity based on tumor intrinsic and tumor extrinsic effects on microenvironment

Highlights ITK inhibition novel mechanism of action, aligned with recently presented immunologic and biomarker data from the soquelitinib Phase 1 atopic dermatitis trial 

SOUTH SAN FRANCISCO, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the publication of peer-reviewed final data from its Phase 1/1b trial of soquelitinib in patients with T cell lymphoma. The publication in Blood, the journal of the American Society of Hematology, provides the medical and scientific community with clinical and immunologic data supporting the development of soquelitinib in oncology and immune and inflammatory diseases.

“The publication of these data in Blood brings our soquelitinib findings to a wide audience of clinicians and researchers,” said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. “In patients with advanced, aggressive and difficult-to-treat T cell lymphomas, soquelitinib demonstrated durable responses, including complete responses, maintained for more than two years in some patients and a median overall survival exceeding two years. This compares favorably to currently available therapies, providing the rationale for our ongoing registration Phase 3 trial in relapsed/refractory PTCL. The peer-reviewed data also detail soquelitinib’s mechanism of action, with selective ITK inhibition driving Th1 skewing and blocking of Th2 and Th17 differentiation. We believe these data support soquelitinib’s broad potential across immune and inflammatory diseases, reinforcing our development strategy including our ongoing SIERRA1 Phase 2 trial in atopic dermatitis and planned trials in hidradenitis suppurativa and asthma.”

The Phase 1/1b trial enrolled 75 heavily pre-treated patients (27 in dose escalation portion and 48 in dose expansion portion) with various T cell lymphomas, including peripheral T cell lymphoma (PTCL), T follicular helper cell lymphoma (TFHC), natural killer cell T cell lymphoma (NKTCL), cutaneous T cell lymphoma (CTCL), anaplastic large cell lymphoma (ALCL) and adult T cell lymphoma/leukemia (ATLL). The median number of prior therapies was three (range 1-18), with only 31% achieving an objective response to their most recent prior therapy. In the dose escalation portion, patients received a twice-daily dose of soquelitinib of 100 mg, 200 mg, 400 mg or 600 mg, and the 200 mg twice-daily dose was selected for the dose expansion portion based on biomarker studies which demonstrated that doses of 200 mg or higher achieved complete occupancy of the ITK target with the drug.

Soquelitinib was well tolerated across all dose cohorts up to 600 mg twice-daily, with no dose-limiting toxicities or significant adverse events and, notably, no myelosuppression or immunosuppression. In the 200 mg twice-daily cohort (N=36), there were objective and durable tumor responses, including six complete responses. Within this group, patients with one to three prior therapies were determined to be most likely to respond to therapy (N=24) and achieved the following results: objective responses in 9 of 24 patients (six complete and three partial), a median progression-free survival of 6.2 months with 30% of patients progression-free at 18 months, and a median overall survival of 28.1 months with 67% of patients alive at 24 months.

The publication also characterizes soquelitinib’s mechanism of action. In vitro studies showed that appropriate doses resulted in Th1 skewing by blocking Th2 differentiation, and biomarker analyses of patient blood and tumor samples also demonstrated this effect in vivo, with increased Th1 cells and reduced serum IL-5. In six patients with paired tumor biopsies analyzed by RNA sequencing, treatment increased intratumoral Th1 cells by day 8, which Corvus believes reflects the direct linkage between the drug’s clinical activity and its underlying immunobiology. These findings are consistent with an anti-tumor mechanism of action involving both direct effects on the tumor (tumor intrinsic) as well as a tumor extrinsic effect on the tumor microenvironment leading to an enhanced host immune response against the tumor.

The publication is available online at the Blood website and on the Publications and Presentations page of the Corvus website. It will also be published in an upcoming print edition of the journal.

Corvus is currently enrolling patients in a registration Phase 3 clinical trial of soquelitinib in patients with relapsed/refractory PTCL at multiple clinical sites. This randomized controlled trial is anticipated to enroll a total of 150 patients with relapsed/refractory PTCL and is evaluating soquelitinib versus physicians’ choice of either belinostat or pralatrexate. The primary endpoint of the trial is progression-free survival. There are no FDA fully approved agents for the treatment of relapsed/refractory PTCL, and the FDA has granted soquelitinib Orphan Drug Designation for the treatment of T cell lymphoma and Fast Track designation for treatment of adult patients with relapsed or refractory PTCL after at least 2 lines of systemic therapy. 

About

Blood


Blood is the flagship journal of the American Society of Hematology, providing an international forum for the publication of original articles describing basic laboratory, translational, and clinical investigations in hematology.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of immune diseases and cancer. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Soquelitinib is being evaluated in a registration Phase 3 clinical trial for relapsed/refractory PTCL and in a Phase 2 clinical trial for the treatment of atopic dermatitis. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com or follow the Company on LinkedIn.

About Soquelitinib

Soquelitinib (formerly CPI-818) is an investigational small molecule drug given orally designed to selectively inhibit ITK (interleukin-2-inducible T cell kinase), an enzyme that is expressed predominantly in T cells and plays a role in T cell and natural killer (NK) cell immune function. Soquelitinib has been shown to affect T cell differentiation and induce the generation of Th1 helper cells while blocking the development of both Th2 and Th17 cells and production of their secreted cytokines. Th1 T cells are required for immunity to tumors, viral infections and other infectious diseases. Th2 and Th17 helper T cells are involved in the pathogenesis of many autoimmune and allergic diseases. Recent studies have demonstrated that ITK controls a switch between the differentiation of Th17 proinflammatory cells and T regulatory suppressor cells. Inhibition of ITK leads to a shift toward T regulatory cell differentiation, which has the potential to suppress autoimmune and inflammatory reactions. The Company believes the inhibition of specific molecular targets in T cells may be of therapeutic benefit for patients with autoimmune and allergic diseases and in cancers, including solid tumors. Based on interim results from a Phase 1/1b clinical trial in patients with refractory T cell lymphomas, which demonstrated tumor responses in very advanced, refractory, difficult to treat T cell malignancies, the Company is enrolling a registration Phase 3 clinical trial (NCT06561048) of soquelitinib in patients with relapsed/refractory PTCL. Soquelitinib is also now being investigated in a randomized placebo-controlled Phase 2 clinical trial in patients with atopic dermatitis. A publication describing the chemistry, enzymology and biology of soquelitinib appeared in npj Drug Discovery in December 2024 and is available online at the Nature website and on the Publications and Presentations page of the Corvus website.

About Peripheral T Cell Lymphoma

Peripheral T cell lymphoma is a heterogeneous group of malignancies accounting for about 10% of non-Hodgkin’s lymphomas (NHL) in Western populations, reaching 20% to 25% of NHL in some parts of Asia and South America. The most common subtypes are PTCL-not otherwise specified (PTCL-NOS) and T follicular helper cell lymphoma. First line treatment for these diseases is typically combination chemotherapy; however, approximately 75% of patients either do not respond or relapse within the first two years. Patients in relapse are treated with various chemotherapy agents but have poor overall outcomes with median progression-free survival in the three to four month range and overall median survival of six to 12 months. There are no approved drugs in relapsed/refractory PTCL based on randomized trials.

PTCL is a disease of mature helper T cells that express ITK, often containing numerous genetic mutations and frequently associated with viral infection. Most often the malignant cells of PTCL express a Th2 phenotype.

About Atopic Dermatitis

Atopic dermatitis, also called eczema, is a chronic disease that can cause inflammation, redness, scaly patches, blisters and irritation of the skin. It affects up to 20% of children and up to 10% of adults, and treatments include topical therapies, oral therapies and systemic injectable biologic therapies. It is frequently associated with other allergic disorders such as food allergies and asthma. Atopic dermatitis, like asthma and allergy, involves the participation of Th2 lymphocytes which secrete cytokines that result in inflammation. Soquelitinib has been shown in preclinical and clinical studies to inhibit cytokine production from Th2 lymphocytes.

Forward-Looking Statements

This press release contains forward-looking statements, including statements related to Phase 1 data from the soquelitinib Phase 1/1b T cell lymphoma trial as support for ongoing and planned trials; the potential safety, tolerability, clinical benefit and efficacy of the Company’s product candidates, including soquelitinib; the potential use of soquelitinib to improve therapy for a broad range of patients with T cell lymphoma, atopic dermatitis, other immune diseases and cancers; and clinical strategy and the design of clinical trials, including the timeline for initiation, target or expected number of patients to be enrolled, dose levels, number of sites and other product development milestones.. All statements other than statements of historical fact contained in this press release are forward-looking statements. These statements often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may” or similar expressions. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the Securities and Exchange Commission on August 6, 2026, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: no head-to-head clinical trials have been conducted comparing soquelitinib to available therapies for patients with T cell lymphoma; the Company’s ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials of its product candidates; the accuracy of the Company’s estimates relating to its ability to initiate and/or complete preclinical studies and clinical trials and release data from such studies and clinical trials; the results of preclinical studies and interim data from clinical trials not being predictive of future results; the Company’s ability to enroll sufficient numbers of patients in its clinical trials; the unpredictability of the regulatory process; regulatory developments in the United States and foreign countries; the costs of clinical trials may exceed expectations; and the Company’s ability to raise additional capital. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and the timing of events and circumstances and actual results could differ materially from those projected in the forward-looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

INVESTOR CONTACT:

Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
[email protected]

MEDIA CONTACT:

Julia Stern
Real Chemistry
+1-949-903-4750
[email protected]

NEW YORK, Aug. 27, 2026 (GLOBE NEWSWIRE) — Veea Inc. (“Veea”), a leader in secure edge computing, connectivity and AI-enabled solutions, and Telarus, a leading technology services distributor, today announced the signing of a Technology Services Distribution Agreement designed to expand the availability of Veea’s innovative technology solutions through Telarus’ extensive network of technology advisors and channel partners.

The agreement establishes Telarus as a distribution partner for Veea’s portfolio of secure connectivity and edge technology solutions, enabling Telarus partners to address growing customer demand for reliable connectivity, cybersecurity, intelligent networking and edge computing through an integrated technology platform.

“Partnering with Telarus represents an important step in our strategy to scale Veea platform products through a major sales channel,” said Helder Antunes, EVP-Chief Revenue Officer of Veea. “Businesses increasingly need more than connectivity. They need secure, intelligent and easily managed infrastructure that can support multimodal agentic AI and their operations without the complexity and cost traditionally associated with enterprise technology. Telarus has built an exceptional ecosystem of technology advisors and partners, and we believe this relationship can help bring Veea’s capabilities to a much broader customer base.”

Telarus brings extensive experience in helping businesses evaluate and deploy communications, cloud, cybersecurity, networking and other technology solutions through its global network of independent technology advisors. The agreement gives those advisors access to Veea solutions that can be integrated into broader technology strategies for customers ranging from small and medium-sized businesses to distributed enterprises.

“Customers are looking for technology that is easier to deploy, easier to manage and capable of solving multiple infrastructure challenges at once,” said Sumera Riaz, VP of Cybersecurity at Telarus. “Veea’s combination of secure connectivity, edge computing, networking and intelligent applications gives our partners another compelling solution to bring to their customers. We are excited to work with Veea and our channel community to accelerate adoption of these technologies.”

Bringing Enterprise Capabilities to a Broader Market

Veea’s technology platform is designed to converge networking, cybersecurity, edge computing and intelligent applications into an integrated architecture. Its solutions can support applications including secure connectivity, SD-WAN, Zero Trust security, IoT, video intelligence, AI-enabled services and edge computing.

This integrated approach is particularly relevant for organizations with distributed locations and limited internal IT resources, where managing multiple point solutions can increase cost, complexity and security risk.

Through the Telarus channel, Veea expects to expand its reach into new markets and verticals while enabling technology advisors to offer customers a broader portfolio of solutions addressing connectivity, security and digital transformation.

The agreement also creates opportunities for Telarus partners to develop recurring revenue opportunities around managed connectivity, cybersecurity, edge computing and intelligent applications.

A Platform for Growth

The relationship between Veea and Telarus reflects the companies’ shared commitment to simplifying the adoption of advanced technology.

By combining Veea’s technology platform with Telarus’ channel expertise, partner ecosystem and distribution capabilities, the companies intend to help businesses modernize their technology infrastructure while reducing deployment complexity and improving security.

About Veea

Veea Inc. (NASDAQ: VEEA) is a global leader in AI-driven edge infrastructure. Founded in 2014 and headquartered in New York City, Veea enables enterprises, service providers, and public sector organizations to deploy AI-powered applications and services at the edge. Built on Veea-developed and third-party devices, the VeeaONE platform integrates connectivity, computing, cybersecurity, and storage into a unified, hyperconverged network solution, delivered through a full software stack spanning edge to cloud — bringing AI to deployments that range from SMBs to enterprise campuses, smart industries, and remote communities. With more than 123 patents across related technology domains, Veea has been recognized by Gartner for its innovations in edge computing. For more information, visit www.veea.com.

About Telarus

Telarus, a premier global technology services distributor, has devoted over two decades to driving technology advisor impact and growth through deep market insights and experience, a partnership focus, and a comprehensive set of services, solutions, and tools. With a focus on collaboration with advisors and suppliers, Telarus enables technology advisors to source, purchase, and implement the right technology for the greatest impact. To learn more, visit www.telarus.com.    

Media Contact

Thomas Latiolais
Veea Inc.
[email protected]

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, including statements regarding, among other things, the plans, strategies and prospects, both business and financial, of Veea. These statements are based on the beliefs and assumptions of Veea. Although Veea believes that its plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, Veea cannot assure you that it will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Generally, statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies, events or results of operations, and any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These statements may be preceded by, followed by or include the words “anticipate,” “believe,” “could,” “continue,” “estimate,” “expect,” “forecast,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “project,” “scheduled,” “seek,” “should,” “will” or similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements contained in this press release include, but are not limited to, statements about (i) Veea’s ability to maintain adequate operational and financial resources, including the ability to raise sufficient capital and/or generate sufficient cash flows; (ii) Veea’s ability to achieve its current growth strategy and its ability to grow revenue and become profitable; (iii) the market acceptance of Veea’s platform and products; (iv) Veea’s reliance on distribution and partnering arrangements; and (v) Veea’s ability to compete against industry competitors.

You are cautioned not to place undue reliance on forward-looking statements, which only speak as of the date made, are not a guarantee of future performance and are subject to a number of uncertainties, risks, assumptions and other factors, many of which are outside the control of Veea. Veea expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the expectations of Veea with respect thereto or any change in events, conditions or circumstances on which any statement is based.

• New CRADA drives joint development of advanced materials, AI/ML process optimization, equipment enhancements, and scalable production solutions
• Positions additive manufacturing to support nuclear energy systems, energy infrastructure resilience, and national security missions
• Creates pathway from collaborative research to workforce training, technology transfer and commercial-scale industrial applications

ROCK HILL, S.C., Aug. 27, 2026 (GLOBE NEWSWIRE) — 3D Systems (NYSE: DDD) today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with Savannah River National Laboratory (SRNL) to accelerate innovation in additive manufacturing (AM) for advanced energy generation and national security applications. The partnership centers on SRNL’s Advanced Manufacturing Collaborative (AMC), leveraging the facility’s unique position as South Carolina’s only national laboratory-operated site located on a public university campus.

Through this CRADA, SRNL and 3D Systems will jointly pursue advancements in materials development, equipment enhancements, artificial intelligence and machine learning-enabled process optimization, manufacturing systems, cybersecurity, and workforce development training. These efforts will drive the creation of next-generation AM materials, real-time process optimization tools, and scalable production solutions, along with the workforce that will enable the rapid adoption of advanced manufacturing technologies.

“We look forward to partnering with SRNL at the Advanced Manufacturing Collaborative and deploying 3D Systems’ leading AM technologies,” said Jeff Graves, President and CEO of 3D Systems. “This agreement demonstrates the impact and importance of high-quality 3D printing materials and technologies on key industrial markets, particularly energy and national security, and on developing the skilled workforce those markets require.”

A primary emphasis of the collaboration is the application of additive manufacturing to critical energy challenges, with particular relevance to nuclear energy and broader energy infrastructure. Additive manufacturing enables the fabrication of complex components from advanced alloys that are difficult or impossible to produce using conventional methods. This includes high-temperature nickel-based superalloys and other radiation-tolerant materials for intricate heat exchangers with internal cooling channels, reactor internals, pumps, valves, and other high-performance components essential to advanced nuclear systems. These capabilities support improved performance under extreme conditions, reduced material waste, greater design freedom, and enhanced supply-chain resilience, all essential for advanced nuclear reactor systems, fusion energy technologies, power generation equipment, and U.S. energy infrastructure modernization.

The partnership is timed to support a period of renewed investment and innovation across the U.S. nuclear and energy sectors. Advanced reactor designs, small modular reactors (SMRs), and related energy initiatives are driving demand for manufacturing approaches that can accelerate development cycles, reduce costs, and strengthen domestic production capacity. This collaboration is timely given the projected expansion of advanced nuclear capacity worldwide. According to the International Energy Agency, small modular reactor capacity could grow to roughly 40 gigawatts under current policies or up to 120 gigawatts in accelerated scenarios by 2050, supporting rising demand for reliable, low-carbon power in applications ranging from data centers and industrial heat to grid stability and energy security¹. By combining 3D Systems’ commercial AM platforms and materials expertise with SRNL’s deep domain knowledge in nuclear materials, environmental stewardship, and energy resilience, the collaboration aims to help bridge laboratory innovation with industrial readiness.

“This collaboration positions SRNL and 3D Systems to deliver groundbreaking additive manufacturing technologies, strengthen U.S. manufacturing competitiveness, and drive forward the next era of AM innovation,” said Roderick Jackson, associate laboratory director for science, energy and innovation at SRNL.

While structured as a cooperative research and development agreement, the CRADA is intentionally designed to create a clear pathway from foundational research to technology transfer and commercial application. Cutting-edge 3D Systems equipment has been installed at the AMC and is supported by facility upgrades and resident AM subject-matter experts. This infrastructure will enable both world-class research and the demonstration of production-ready processes, positioning the partners to develop scalable manufacturing solutions with broader implications for high-value industrial markets including nuclear energy, aerospace and defense, and environmental technologies.

“This agreement underscores SRNL’s commitment to building world-class research capabilities, leveraging partnerships to enhance its competitive edge and solidify its presence as a leader in AM technologies,” said G. Jeremy Leong, director of the Advanced Manufacturing Collaborative at SRNL.

In addition to technology development, the partnership expands opportunities for training and developing the next generation of AM scientists, engineers, and technicians, strengthening the regional and national advanced manufacturing workforce.

About the Advanced Manufacturing Collaborative and SRNL

SRNL’s Advanced Manufacturing Collaborative opened just one year ago with a bold purpose and a clear vision as a nexus of innovation. Today, the AMC stands proudly as a place where industry, academia, and government come together to pioneer technologies that advance national security, environmental stewardship, and energy resilience. It has quickly become a home where collaboration thrives, integration drives impact, and ideas are transformed into purposeful solutions real world solutions for the nation. The AMC officially opened on August 7, 2025.

Savannah River National Laboratory is a multi-program federally funded research and development center managed and operated by Battelle Savannah River Alliance for the U.S. Department of Energy’s Office of Environmental Management. EM transforms the nation’s environmental liabilities into opportunities for innovation, job creation, and economic growth, while ensuring safe, secure and prosperous communities across America.

About 3D Systems

For 40 years, Chuck Hull’s curiosity and desire to improve the way products were designed and manufactured gave birth to 3D printing, 3D Systems, and the additive manufacturing industry. Since then, that same spark continues to ignite the 3D Systems team as we work side-by-side with our customers to change the way industries innovate. As a full-service solutions partner, we deliver industry-leading 3D printing technologies, materials, and software to high-value markets such as medical and dental; aerospace, space and defense; transportation and motorsports; AI infrastructure; and durable goods. Each application-specific solution is powered by the expertise and passion of our employees who endeavor to achieve our shared goal of Transforming Manufacturing for a Better Future. More information on the company is available at www.3dsystems.com.

Contacts

3D Systems Investor Contact: [email protected]
3D Systems Media Contact: [email protected]
SRNL Media Relations: [email protected]

Forward-Looking Statements

Certain statements made in this release that are not statements of historical or current facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the timing of product launches, regulatory approvals, market opportunities, expected revenue impact, and shareholder value. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. In many cases, forward-looking statements can be identified by terms such as “believes,” “belief,” “expects,” “may,” “will,” “estimates,” “intends,” “anticipates” or “plans” or the negative of these terms or other comparable terminology. Forward-looking statements are based upon management’s beliefs, assumptions, and current expectations and may include comments as to the company’s beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside the control of the company. The factors described under the headings “Forward-Looking Statements” and “Risk Factors” in the company’s periodic filings with the Securities and Exchange Commission, as well as other factors, could cause actual results to differ materially from those reflected or predicted in forward-looking statements. Although management believes that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not, be relied upon as a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at which such performance or results will be achieved. The forward-looking statements included are made only as of the date of the statement. 3D Systems undertakes no obligation to update or review any forward-looking statements made by management or on its behalf, whether as a result of future developments, subsequent events or circumstances or otherwise.

¹ “The Path to a New Era for Nuclear Energy”. International Energy Agency, (iea) January 13, 2025 

BURLINGTON, Mass. and JERUSALEM, Aug. 27, 2026 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the publication of new peer-reviewed data demonstrating significant reductions in suicidal ideation among patients with Major Depressive Disorder (MDD) treated with Deep Transcranial Magnetic Stimulation (Deep TMS™).

The publication, entitled “Effects of H-coil TMS on suicidality in major depression: A secondary analysis of data from a multisite randomized trial comparing accelerated to once-a-day stimulation,” was published in the Journal of Affective Disorders. The analysis evaluated suicidality outcomes from BrainsWay’s previously published multisite randomized non-inferiority clinical trial which had compared its SWIFT™ accelerated protocol with its standard once-daily Deep TMS protocol and which had resulted in the FDA’s September 2025 clearance of SWIFT.

Key Findings

• Patients receiving Deep TMS demonstrated significant reductions in suicidal ideation over the course of treatment. Of the 89 patients enrolled in the study, using the Scale for Suicide Ideation (SSI), the number of patients exhibiting signs of suicide ideation (SSI>0) decreased from 22.5% (20/89) at baseline to 6.7% (6/89) after 6 weeks of treatment, a 70% relative reduction.
• Reductions were observed with both the SWIFT accelerated protocol and standard once-daily Deep TMS treatment. The median time to improvement in suicidality (i.e. defined in the study as a reduction of at least one point on the SSI) was 10 days in the group of patients treated with SWIFT, and 13 days in the group treated with the standard Deep TMS protocol, a statistically significant difference.

The results add to a growing body of research published in 2026 on the potential role Deep TMS can play in reducing suicidality, a devastating symptom associated with Major Depressive Disorder (MDD). A separate randomized, sham-controlled study of hospitalized patients with MDD and active suicidality found that patients receiving active H1 or H7 Deep TMS showed reductions in suicidal-ideation intensity, while those receiving sham treatment did not. In addition, a 2026 review of 108 studies examining treatments for suicidality concluded that TMS was associated with reductions in suicidal ideation and noted comparatively durable effects following TMS treatment.

“Suicidal ideation remains one of the most serious and urgent challenges in major depression. Seeing multiple independent publications converge around the potential of Deep TMS to meaningfully reduce suicidal ideation is highly encouraging and reinforces our commitment to advancing the science in an area of profound unmet need” said Hadar Levy, Chief Executive Officer of BrainsWay.

Deep TMS is FDA-cleared for the treatment of Major Depressive Disorder. It is not FDA-cleared for the treatment or prevention of suicidal ideation or suicidal behavior.

About BrainsWay

BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with operations in the United States and Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.

Forward-Looking Statement

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “targets,” “believes,” “hopes,” “potential” or similar words, and also includes any financial guidance and projections contained herein. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Historical results or conclusions from scientific research and clinical studies – especially secondary/retrospective analysis data such as that reflected in this press release – do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the failure to realize anticipated synergies and other benefits of the proposed transaction; the failure of our investments in management services organizations and/or other clinic-related entities to produce profitable returns; inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company’s anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company’s intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements.

Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission.

Contacts:

BrainsWay:

Ido Marom
Chief Financial Officer
[email protected]

Investors:

Brian Ritchie
LifeSci Advisors
[email protected]